Protein degradation as a target for anticancer therapy: molecular mechanisms of efficacy and acquired resistance to proteasome and aminopeptidase inhibitors

被引：0
|
作者：
Peters, G. J. [1 ]
Ossenkoppele, G. J. [2 ]
Cloos, J. [2 ]
Jansen, G. [3 ]
机构：
[1] Vrije Univ Amsterdam, Med Ctr, Dept Med Oncol, Amsterdam, Netherlands
[2] Vrije Univ Amsterdam, Med Ctr, Dept Pediat Oncol Hematol, Amsterdam, Netherlands
[3] Vrije Univ Amsterdam, Med Ctr, Dept Rheumatol, Amsterdam, Netherlands
来源：
AMINO ACIDS | 2016年 / 48卷 / 02期
关键词：
D O I：
暂无
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
引用
收藏
页码：616 / 616
页数：1
相关论文
共 38 条
  • [31] Recent understanding of the molecular mechanisms for the efficacy and resistance of EGF receptor-specific tyrosine kinase inhibitors in non-small cell lung cancer
    Nakata, Asuka
    Gotoh, Noriko
    EXPERT OPINION ON THERAPEUTIC TARGETS, 2012, 16 (08) : 771 - 781
  • [32] T-cell lymphoma as a model for the use of histone deacetylase inhibitors in cancer therapy: impact of depsipeptide on molecular markers, therapeutic targets, and mechanisms of resistance
    Piekarz, RL
    Robey, RW
    Zhan, ZR
    Kayastha, G
    Sayah, A
    Abdeldaim, AH
    Torrico, S
    Bates, SE
    BLOOD, 2004, 103 (12) : 4636 - 4643
  • [33] Targeting Polyubiquitin Signals With Macrocyclic Peptides to Modulate Protein Degradation: Mechanisms of Selective Recognition of Long Lys48-linked Chains by Macrocyclic Peptide-inhibitors of Ubiquitin-Proteasome System
    Fushman, David
    Lemma, Betsegaw
    Zhang, Di
    Vamisetti, Ganga B.
    Wentz, Bryan G.
    Suga, Hiroaki
    Brik, Ashraf
    Lubkowski, Jacek
    PROTEIN SCIENCE, 2024, 33 : 200 - 200
  • [34] HER2/PIK3CAH1047R transgenic tumors develop acquired resistance to triple therapy with trastuzumab, pertuzumab, and PI3K inhibitors via multiple mechanisms
    Hanker, Ariella B.
    Young, Christian D.
    Stricker, Thomas P.
    Cook, Rebecca S.
    Arteaga, Carlos L.
    CANCER RESEARCH, 2014, 74 (19)
  • [35] HER2/PIK3CAH1047R transgenic mammary tumors develop acquired resistance to triple therapy with trastuzumab, pertuzumab and PI3K inhibitors via multiple mechanisms
    Hanker, Ariella B.
    Bulen, Benjamin
    Brewer, Monica Red
    Young, Christian D.
    Farrar, Kirsten M.
    Cook, Rebecca S.
    Stricker, Thomas P.
    Arteaga, Carlos L.
    CANCER RESEARCH, 2015, 75
  • [36] Molecular Mechanisms of Alzheimer's Disease Induced by Amyloid-β and Tau Phosphorylation Along with RhoA Activity: Perspective of RhoA/Rho-Associated Protein Kinase Inhibitors for Neuronal Therapy
    Ahn, Eun Hee
    Park, Jae-Bong
    CELLS, 2025, 14 (02)
  • [37] Impact of clinical features on the efficacy of osimertinib therapy in patients with T790M-positive non-small cell lung cancer and acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors
    Kato, Yasuhiro
    Hosomi, Yukio
    Watanabe, Kageaki
    Yomota, Makiko
    Kawai, Shoko
    Okuma, Yusuke
    Kubota, Kaoru
    Seike, Masahiro
    Gemma, Akihiko
    Okamura, Tatsuru
    JOURNAL OF THORACIC DISEASE, 2019, 11 (06) : 2350 - 2360
  • [38] New insights into the molecular mechanisms underlying sensitivity/resistance to the atypical retinoid ST1926 in acute myeloid leukaemia cells: The role of histone H2A.Z, cAMP-dependent protein kinase A and the proteasome
    Fratelli, Maddalena
    Fisher, James Neil
    Paroni, Gabriela
    Di Francesco, Angela Maria
    Pierri, Filomena
    Pisano, Claudio
    Godl, Klaus
    Marx, Sandra
    Tebbe, Andreas
    Valli, Claudia
    Gianni, Maurizio
    Stravalaci, Matteo
    Gobbi, Marco
    Terao, Mineko
    Garattini, Enrico
    EUROPEAN JOURNAL OF CANCER, 2013, 49 (06) : 1491 - 1500
1234